Prostatilen solution for injection 2 mg/2 ml ampoule 2 ml No. 10

Instructions Prostatilen solution for injection 2 mg/2 ml ampoule 2 ml No. 10

Composition

active ingredient: prostatilen;

1 ampoule (2 ml of solution) contains prostatilen (aqueous extract from the prostate glands of sexually mature bulls) in terms of peptides 2 mg;

excipients: glycine, sodium chloride, water for injection.

Dosage form

Solution for injection.

Main physicochemical properties: transparent, colorless or slightly yellowish liquid.

Pharmacotherapeutic group

Drugs used in urology. Drugs used in benign prostatic hypertrophy.

ATX code G04C X.

Pharmacological properties

Pharmacodynamics

Prostatilen has a specific organotropic effect on the prostate gland. In diseases of the latter, the drug as a means of pathogenetic therapy normalizes the processes of microcirculation and platelet-vascular hemostasis, reduces or eliminates tissue edema, leukocyte infiltration (including reducing the content of leukocytes in the gland's secretion), exerts an indirect bacteriostatic effect on the microflora of the secretion, reduces the titer of the detected pathogen up to absolute sterility or inhibits the viability of microorganisms. Prostatilen normalizes spermatogenesis (increases the number and mobility of sperm), exerts a modulating effect on the state of T- and B-lymphocytes, increases the body's nonspecific resistance, regulates the tone of the bladder muscles, including the tone of the detrusor.

Pharmacokinetics

As a peptide drug, prostatilen is broken down by cellular proteases to amino acids. Prostatilen and its metabolites are excreted in the urine. The drug does not have a cumulative effect.

Indication

Chronic prostatitis.

Prostate adenoma, age-related dysfunctions of its functions and related disorders of the act of urination.

Complications after prostate surgery.

Interoceptive copulatory dysfunction.

Male infertility.

Contraindication

Increased individual sensitivity to the components of the drug and bovine prostate proteins.

Interaction with other medicinal products and other types of interactions

Not studied.

Application features

When treating with the drug, it is recommended to analyze clinical indicators of prostate activity.

Use with caution in patients with atherosclerosis, increased risk of thromboembolism. With prolonged use of the drug, it is necessary to monitor blood clotting time.

Use during pregnancy or breastfeeding

The medicine is not intended for use by women.

Ability to influence reaction speed when driving vehicles or other mechanisms

Not studied.

Method of administration and doses

It is used to treat adult men, including elderly patients. It is administered intramuscularly.

The drug is administered daily, 1–2 ampoules once a day.

The duration of the treatment course is 5–10 days.

If necessary, a repeated course is carried out (after 1–6 months).

Children

The medicine is not used in children.

Overdose

No cases of overdose have been reported to date.

Possible dyspeptic disorders, fatigue, general weakness, headache, creatinuria, increased creatine kinase activity, increased cholesterol and triglyceride concentrations, decreased serum thyroxine and triiodothyronine concentrations, increased urinary estrogen and androgen content. There is no specific antidote. Treatment is symptomatic.

Side effects

Allergic reactions are possible.

Expiration date

3 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Incompatibility

The drug should not be mixed with other drugs in the same syringe.

Packaging

2 ml in an ampoule, 100 ampoules in a pack or 5 ampoules in a blister, 1 or 2 blisters in a pack.

Vacation category

According to the recipe.

Producer

Private Joint-Stock Company "Lekhim-Kharkiv".

Location of the manufacturer and address of its place of business

Ukraine, 61115, Kharkiv region, Kharkiv city, Severyna Pototskoho street, building 36.